Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ramsdens reports record first half as gold prices surge

(Sharecast News) - Ramsdens shares popped on Wednesday after the pawnbroker, jewellery and currency exchange firm revealed record results for its first half on the back of gold prices hitting an all-time high. The company said that, despite the additional hit from higher labour costs this year - owing to increases in national insurance contributions and the national living wage - full-year profits are now expected to exceed £15m, up from previous guidance of "at least £13m".

Revenues in the six months to 31 March totalled £51.6m, up 18% over the year before.

After Ramsdens buys unwanted jewellery, gold and other precious metals, they are either sold on second-hand - reflected in jewellery retail revenues - or smelted and sold to a bullion dealer, generating precious metals revenues.

With the average price of 9ct gold surging to £26.22 from £19.45 the year before, precious metals revenues were 31% higher at £18.4m, while jewellery retail revenues were up 18% at £20.7m.

Pre-tax profits for the half were up 54% year-on-year at a record £6.1m, leading the board to approve a 25% increase in the interim dividend to 4.5p per share.

"While all of our income streams achieved growth during the first half, our purchase of precious metals segment delivered an outstanding performance, with the well-publicised and sustained exceptionally high gold price encouraging more customers to sell unwanted jewellery," said chief executive Peter Kenyon.

"Looking ahead, the group is well placed with continued opportunities to grow. We have a strong balance sheet and good cash generation which provides options to how we allocate our capital."

Shares were 7.6% higher at 355p by 1102 BST, pushing the year-to-date gain to over 52%.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.